These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34034931)

  • 1. Re: 'High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'.
    Hara A; Matsuda M; Ishii A; Yoshioka T
    Eur J Cancer; 2021 Aug; 153():265-266. PubMed ID: 34034931
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'.
    Cantini L; Pecci F; Dammeijer F; Aerts JGJV; Berardi R
    Eur J Cancer; 2021 Aug; 153():267-269. PubMed ID: 34154882
    [No Abstract]   [Full Text] [Related]  

  • 3. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
    Cantini L; Pecci F; Hurkmans DP; Belderbos RA; Lanese A; Copparoni C; Aerts S; Cornelissen R; Dumoulin DW; Fiordoliva I; Rinaldi S; Aerts JGJV; Berardi R
    Eur J Cancer; 2021 Feb; 144():41-48. PubMed ID: 33326868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IASLC 2020 World Conference on Lung Cancer.
    Venkatesan P
    Lancet Respir Med; 2020 Oct; 8(10):e76. PubMed ID: 32866439
    [No Abstract]   [Full Text] [Related]  

  • 5. [The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations].
    Jassem J; Biernat W; Bryl M; Chorostowska-Wynimko J; Dziadziuszko R; Krawczyk P; Kordek R; Kowalski DM; Krzakowski M; Olszewski W; Orłowski T; Ramlau R; Rzyman W
    Pneumonol Alergol Pol; 2014; 82(2):133-49. PubMed ID: 24615197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
    Uprety D
    Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune checkpoint inhibitor therapy for malignant pleural mesothelioma.
    Nowak AK; Chin WL; Keam S; Cook A
    Lung Cancer; 2021 Dec; 162():162-168. PubMed ID: 34823106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody drug conjugates in thoracic malignancies.
    Pacheco JM; Camidge DR
    Lung Cancer; 2018 Oct; 124():260-269. PubMed ID: 30268471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.
    Perera ND; Mansfield AS
    Curr Oncol Rep; 2022 Nov; 24(11):1413-1423. PubMed ID: 35657483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors in mesothelioma: a turning point.
    Ceresoli GL; Pasello G
    Lancet; 2021 Jan; 397(10272):348-349. PubMed ID: 33485463
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel therapies for malignant pleural mesothelioma.
    Scherpereel A; Wallyn F; Albelda SM; Munck C
    Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
    Mohamed H; Eltobgy M; Abdel-Rahman O
    Anticancer Agents Med Chem; 2017; 17(9):1228-1233. PubMed ID: 28042777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
    Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesothelioma: closer to the target?
    Pass HI
    Lancet Oncol; 2013 May; 14(6):448-9. PubMed ID: 23583605
    [No Abstract]   [Full Text] [Related]  

  • 16. A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
    Chen Y; Chen B; Zhu X; Zhong J
    Lung Cancer; 2018 Feb; 116():96-98. PubMed ID: 29146159
    [No Abstract]   [Full Text] [Related]  

  • 17. Eve of the third millennium, providing an update on the management of non-small cell lung cancer (NSCLC).
    Le Chevalier T
    Anticancer Drugs; 2001 Jul; 12 Suppl 3():S1. PubMed ID: 11556248
    [No Abstract]   [Full Text] [Related]  

  • 18. Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.
    Adusumilli PS
    Cancer; 2014 Nov; 120(21):3268-71. PubMed ID: 24989696
    [No Abstract]   [Full Text] [Related]  

  • 19. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
    Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
    Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.
    Petri GL; Cascioferro S; Parrino B; Peters GJ; Diana P; Giovannetti E
    Pharmacogenomics; 2018 Jul; 19(10):811-814. PubMed ID: 29916298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.